Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging

Bull Exp Biol Med. 2002 Feb;133(2):167-70. doi: 10.1023/a:1015555023692.


Female transgenic FVB mice carrying breast cancer gene HER-2/neu were monthly injected with Vilon or Epithalon (1 microgram subcutaneously for 5 consecutive days) starting from the 2nd month of life. Epithalon markedly inhibited neoplasm development: the maximum size of breast adenocarcinomas was 33% lower than in the control (p < 0.05). The intensity of HER-2/neu mRNA expression in breast tumors of Epithalon-treated mice was 3.7 times lower than in control animals. These results indicate that Epithalon inhibits breast tumor development in transgenic mice, which is probably related to suppression of HER-2/neu expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / metabolism
  • Aging / physiology*
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Dipeptides / therapeutic use*
  • Female
  • Gene Expression
  • Genes, erbB-2*
  • Mammary Neoplasms, Animal / drug therapy*
  • Mammary Neoplasms, Animal / metabolism
  • Mice
  • Mice, Transgenic
  • Oligopeptides / therapeutic use*
  • RNA, Messenger / metabolism
  • Random Allocation


  • Antineoplastic Agents
  • Dipeptides
  • Oligopeptides
  • RNA, Messenger
  • lysylglutamic acid
  • alanyl-glutamyl-aspartyl-glycine